Onconetix Statistics
Total Valuation
Onconetix has a market cap or net worth of $532,307. The enterprise value is -$4.64 million.
Important Dates
The next estimated earnings date is Thursday, June 11, 2026, after market close.
| Earnings Date | Jun 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Onconetix has 692,927 shares outstanding.
| Current Share Class | 692,927 |
| Shares Outstanding | 692,927 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +11.60% |
| Owned by Insiders (%) | 0.51% |
| Owned by Institutions (%) | 2.10% |
| Float | 632,019 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.65 |
| Forward PS | n/a |
| PB Ratio | 0.02 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.66, with a Debt / Equity ratio of 0.00.
| Current Ratio | 0.66 |
| Quick Ratio | 0.61 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.45 |
Financial Efficiency
Return on equity (ROE) is -115.46% and return on invested capital (ROIC) is -23.46%.
| Return on Equity (ROE) | -115.46% |
| Return on Assets (ROA) | -14.93% |
| Return on Invested Capital (ROIC) | -23.46% |
| Return on Capital Employed (ROCE) | -40.18% |
| Weighted Average Cost of Capital (WACC) | 124.29% |
| Revenue Per Employee | $407,686 |
| Profits Per Employee | -$7.77M |
| Employee Count | 2 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 1.70 |
Taxes
In the past 12 months, Onconetix has paid $525 in taxes.
| Income Tax | 525 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.41% in the last 52 weeks. The beta is 3.63, so Onconetix's price volatility has been higher than the market average.
| Beta (5Y) | 3.63 |
| 52-Week Price Change | -97.41% |
| 50-Day Moving Average | 2.21 |
| 200-Day Moving Average | 10.56 |
| Relative Strength Index (RSI) | 34.11 |
| Average Volume (20 Days) | 19,091,987 |
Short Selling Information
The latest short interest is 228,855, so 33.03% of the outstanding shares have been sold short.
| Short Interest | 228,855 |
| Short Previous Month | 680,001 |
| Short % of Shares Out | 33.03% |
| Short % of Float | 36.21% |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, Onconetix had revenue of $815,371 and -$15.53 million in losses. Loss per share was -$82.81.
| Revenue | 815,371 |
| Gross Profit | 632,913 |
| Operating Income | -6.34M |
| Pretax Income | -14.03M |
| Net Income | -15.53M |
| EBITDA | -6.33M |
| EBIT | -6.34M |
| Loss Per Share | -$82.81 |
Full Income StatementBalance Sheet
The company has $5.22 million in cash and $48,774 in debt, giving a net cash position of $5.17 million or $7.46 per share.
| Cash & Cash Equivalents | 5.22M |
| Total Debt | 48,774 |
| Net Cash | 5.17M |
| Net Cash Per Share | $7.46 |
| Equity (Book Value) | 15.76M |
| Book Value Per Share | 50.53 |
| Working Capital | -3.07M |
Full Balance SheetCash Flow
| Operating Cash Flow | -9.68M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 15,170 |
| Net Borrowing | -5.78M |
| Free Cash Flow | -9.68M |
| FCF Per Share | -$13.97 |
Full Cash Flow StatementMargins
| Gross Margin | 77.62% |
| Operating Margin | -778.16% |
| Pretax Margin | -1,720.91% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |